Bombax costatum enhances piroxicam's efficacy: Possible involvement of alpha-2 adrenergic receptor, opioidergic and arachidonic pathways.

BACKGROUND: With increasing drug-herb combination and widespread use of Bombax costatum as analgesic in Africa, this research studies effects of Bombax costatum on piroxicam's efficacy and possible mechanisms of antinociception. MATERIALS AND METHODS: In efficacy studies, four groups of mice were respectively treated with 1mL/kg distilled water, 400mg/kg Bombax costatum, 20mg/kg piroxicam and a combination of both. Acetic acid and hot plate were used to induce pain in mice while prostaglandin-E2 and formalin were used to induce inflammation in rats. For mechanistic studies, different groups of mice were treated intraperitoneally with 2mg/kg naloxone, 1mg/kg yohimbine, 20mg/kg propranolol, 5mg/kg glibenclamide and 1mg/kg prazosin respectively. Two other groups were treated orally with 1mL/kg of the vehicle and 400mg/kg Bombax costatum respectively. 60minutes later, 10mL/kg of 0.6% acetic acid was administered via the intraperitoneal route and number of writhes were observed for 10minutes. RESULTS: Concurrent administration of Bombax costatum and piroxicam decreased the number of writhes significantly (P≤0.001), increased reaction time with decreased paw diameter in comparison to control. Additionally, this drug-herb combination showed enhanced anti-nocipective efficacy than when administered singly. Also, pre-treatment with yohimbine and naloxone significantly (P≤0.01) inhibited the antinociceptive activities of Bombax costatum. CONCLUSION: Bombax costatum posses antinociceptive and anti-inflammatory activities and may involve α-2 adrenergic receptor, opioidergic and arachidonic pathways. In addition, Bombax costaum augments the efficacy of piroxicam and could be of clinical benefits if studied on man.

Bombax Costatum extract abrogates piroxicam-mediated hepatic and gastric toxicities in rats.

OBJECTIVE: Concurrent administration of orthodox drugs and herbs is common in tropical Africa. This study investigates the effect of co-administration of piroxicam and Bombax costatum on hepatic and gastric toxicities and levels of oxidative stress markers. MATERIALS AND METHODS: Twenty male wistar rats were grouped into four. Rats in group one were administered 1mL/kg distilled water as normal control; group two were treated with 400mg/kg of extract; group three were treated with 20mg/kg of piroxicam; while those in group four were treated with both extract and piroxicam at 400mg/kg and 20mg/kg, respectively. All treatments were given orally for 14 days. At the end of the treatment period, the rats were euthanised; blood samples and stomach were collected for determination of hepatic and gastro-toxicity alongside with oxidative stress markers. RESULTS: Treatment with piroxicam alone shows the presence of oxidative stress with marked hepatic and gastric toxicities. Oxidative stress markers, hepatic and gastric toxicity indices after treatment with extract alone and in combination with piroxicam appear like that of the control group. CONCLUSION: Concurrent administration of piroxicam and Bombax costatum prevents piroxicam-induced hepatic and gastric toxicities with a positive effect on antioxidant levels. This may indicate important health benefits of this drug-herb combination.

Otoendoscopy for improved pediatric cholesteatoma removal.

Our objective was to determine the usefulness of intraoperative rigid endoscopy in detecting incompletely removed cholesteatomas, and to learn whether "second-look" procedures are still needed in children. We used 30 degrees, 2.7-mm endoscopes to evaluate the middle ears of 14 children (29 procedures) with cholesteatomas once all visible disease had been removed under the operating microscope. If residual cholesteatoma was seen, removal continued until all disease visualized with the endoscope was removed. If the cholesteatoma was not removed intact, planned exploratory surgery was performed. The rigid endoscope detected incompletely removed cholesteatomas at surgery in 7 of the 29 cases (24%). In 2 of the 11 cases (18%) judged free of cholesteatoma by both otomicroscopy and otoendoscopy, residual disease was found at planned exploratory procedures. While otoendoscopy is clearly useful in detecting incompletely removed cholesteatoma, a substantial rate of residual disease following "complete" removal suggests the continued need for planned exploratory procedures.

Method for removing endobronchial beads.

The development of rigid bronchoscopes, Hopkins rod telescopes, and optical forceps has increased the efficacy and safety of removing endobronchial foreign bodies. These instruments have become the method of choice for managing the majority of foreign bodies. Spherical foreign bodies, such as beads, remain difficult to manage. Securing the foreign body by passing a Fogarty catheter through the lumen, inflating the balloon, and trapping the foreign body between the balloon and the bronchoscope allows controlled removal.

Stump pressure, electroencephalographic changes, and the contralateral carotid artery: another look at selective shunting.

BACKGROUND: Selective shunting during carotid endarterectomy is associated with the lowest operative stroke rate; therefore, patient selection for carotid shunting is critical. Electroencephalography (EEG) can detect ischemic brain cell dysfunction before irreversible injury. The carotid stump back pressure (CSP) has been inconsistent in determining the need for shunting, and contralateral carotid disease has had a variable impact. The purpose of this study was to evaluate CSP and operative EEG changes, and to determine the effect of contralateral carotid artery disease on determining the need for carotid shunting. METHODS: In 140 consecutive carotid procedures, operative EEG and CSP were monitored, and contralateral carotid disease was documented. The carotid stump pressure/mean arterial pressure index (CSP/MAP) was also calculated to determine if this was a better indicator of the need for shunting than the CSP alone. RESULTS: There was a 58% incidence of EEG changes when the CSP was < or = 25 mm Hg, 32% with a CSP of 26 to 50 mm Hg, and 4% with a CSP > 50 mm Hg. There was a 43% incidence of EEG changes and lower CSP among patients with a contralateral occlusion, both of which were significantly different from patients with a patent contralateral carotid artery. Three patients with CSP > 50 mm Hg had EEG changes, but none had a contralateral occlusion. Two patients had permanent neurologic deficits, and 2 had transient deficits. Excluding combined procedures, operative stroke rate was 0.8%. CONCLUSIONS: A CSP of < 50 mm Hg achieved a sensitivity of 89% in patients who developed ischemic EEG changes during carotid clamping, and a pressure > 50 mm Hg had a negative predictive value of 96%. However, a CSP of < 50 mm Hg had a positive predictive value of only 36%. Neither the addition of the status of the contralateral carotid artery or the calculation of the CSP/MAP improved the sensitivity of the CSP in determining the need for shunting. Operative EEG monitoring remains the most sensitive guide to carotid shunting in patients undergoing carotid endarterectomy under general anesthesia.